Megan Ruben
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Megan Ruben has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Yaghy
Department of Ophthalmology and Visual Sciences, University of Massachusetts Chan Medical School, Worcester, MA, USA
2 shared publications A. Evans
Dartmouth Medical School, Hanover, NH; Norris Cotton Cancer Center, Lebanon, NH; PPD Development, Wilmington, NC; Texas Cancer Care, Fort Worth, TX; University of Tennessee, Memphis, TN; Florida Cancer Specialist, Bonita Springs, FL; Appalachian Clinical Research, Pikeville, KY; Dartmouth Hitchcock Medical Center, Lebanon, NH
1 shared publication- Adrian Tien-Chin Fung
Save Sight Institute, Specialty of Clinical Ophthalmology and Eye Health, The University of Sydney, Sydney, New South Wales, Australia
1 shared publication - Alessandro Invernizzi
Eye Clinic, Department of Biomedical and Clinical Science, Luigi Sacco Hospital, University of Milan, Milan, Italy
1 shared publication - Bernard Cole
Department of Mathematics and Statistics, University of Vermont, Burlington, VT, USA
1 shared publication Carol L. Shields
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania
1 shared publication
Latest Publications
- 20 January 2022
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 31 (2) , 263-270
Choroidal Lymphoma: Diagnostic Value of Combined Indocyanine Green Angiography and Optical Coherence Tomography
To compare multimodal imaging findings in patients with choroidal lymphoma (CL).Multicenter retrospective observational case series. Multimodal imaging features of patients with CL were reviewed wi...
- 20 January 2022
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 31 (2) , 263-270
Choroidal Lymphoma: Diagnostic Value of Combined Indocyanine Green Angiography and Optical Coherence Tomography
To compare multimodal imaging findings in patients with choroidal lymphoma (CL).Multicenter retrospective observational case series. Multimodal imaging features of patients with CL were reviewed wi...
- 1 November 2020
- Published by Elsevier in Ophthalmology Retina
- Vol. 4 (11) , 1117
Retinoblastoma Vitreous Seeds Captured on OCT
- 1 November 2020
- Published by Elsevier in Ophthalmology Retina
- Vol. 4 (11) , 1117
Retinoblastoma Vitreous Seeds Captured on OCT
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 7071
Multicenter Web-based phase III study to test the survival equivalence of non-platinum-based (NPB) vs platinum-based (PB) therapy for advanced non-small cell lung cancer (NSCLC): The Dartmouth NPB Chemotherapy Trial (D0112)
7071 Background: For patients (pts) with advanced disease and a good performance status (PS) PB therapy is recommended. To date, the survival benefit of a NPB remains unanswered. This trial is designed to compare the overall survival (OS) of NPB vs PB therapy for advanced NSCLC testing for equivalence. Methods: Pt eligibility: pathological stage IIIB/IV NSCLC, PS 0–2, and no prior chemotherapy. Randomized pts were stratified by stage and PS to arm A: carboplatin AUC = 6 + docetaxel 75 mg/m2 every 3 wks (PB) or arm B: gemcitabine 1 gm/m2 + docetaxel 40 mg/m2 days 1 and 8 every 3 wks (NPB). The primary endpoint is OS. Relative risk (RR) and log-rank will be used to establish therapeutic equivalence (RR 0.8–1.2). Planned sample size 928 pts. This trial is monitored by an independent SDMC and source documentation (SD) for all web-based entries is sought. Results: As of December 2003, 732 pts (367 pts arm A vs 365 pts arm B) are enrolled at 87 sites. Pt characteristics are balanced for gender (38% female), age (median 65, range 36–90), PS (14% PS2), stage (76% stage IV) and histology (51% adenocarcinoma, 20% squamous cell). Arm A received 1,538 cycles and 1,335 cycles in arm B. Serious adverse events (SAEs) occurred 135 pts in arm A and 184 in arm B. Only 30% of all SAEs are attributed to therapy. There were 2 treatment-related deaths, one on each arm. In July 2003 at a predefined interim analysis with 97% of the data SD, 250 deaths occurred among 620 randomized pts. The OS yielded p = 0.38. The 1-year survival rate was 45% for PB and 42% for NPB. The pre-specified stopping rule for superiority was p = 0.01. The SDMC recommended continuation. We anticipate completion by May 2004 and presentation of the final data sets in June 2004. Conclusions: At the predefined interim analysis, there appears to be no statistical survival advantage for platinum or non-platinum-based therapy. At present, there appear to be qualitative and quantitative differences in SAEs. Upon completion, we will definitively comment on the equivalence of a non-platinum-based treatment for this disease.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 7071
Multicenter Web-based phase III study to test the survival equivalence of non-platinum-based (NPB) vs platinum-based (PB) therapy for advanced non-small cell lung cancer (NSCLC): The Dartmouth NPB Chemotherapy Trial (D0112)
7071 Background: For patients (pts) with advanced disease and a good performance status (PS) PB therapy is recommended. To date, the survival benefit of a NPB remains unanswered. This trial is designed to compare the overall survival (OS) of NPB vs PB therapy for advanced NSCLC testing for equivalence. Methods: Pt eligibility: pathological stage IIIB/IV NSCLC, PS 0–2, and no prior chemotherapy. Randomized pts were stratified by stage and PS to arm A: carboplatin AUC = 6 + docetaxel 75 mg/m2 every 3 wks (PB) or arm B: gemcitabine 1 gm/m2 + docetaxel 40 mg/m2 days 1 and 8 every 3 wks (NPB). The primary endpoint is OS. Relative risk (RR) and log-rank will be used to establish therapeutic equivalence (RR 0.8–1.2). Planned sample size 928 pts. This trial is monitored by an independent SDMC and source documentation (SD) for all web-based entries is sought. Results: As of December 2003, 732 pts (367 pts arm A vs 365 pts arm B) are enrolled at 87 sites. Pt characteristics are balanced for gender (38% female), age (median 65, range 36–90), PS (14% PS2), stage (76% stage IV) and histology (51% adenocarcinoma, 20% squamous cell). Arm A received 1,538 cycles and 1,335 cycles in arm B. Serious adverse events (SAEs) occurred 135 pts in arm A and 184 in arm B. Only 30% of all SAEs are attributed to therapy. There were 2 treatment-related deaths, one on each arm. In July 2003 at a predefined interim analysis with 97% of the data SD, 250 deaths occurred among 620 randomized pts. The OS yielded p = 0.38. The 1-year survival rate was 45% for PB and 42% for NPB. The pre-specified stopping rule for superiority was p = 0.01. The SDMC recommended continuation. We anticipate completion by May 2004 and presentation of the final data sets in June 2004. Conclusions: At the predefined interim analysis, there appears to be no statistical survival advantage for platinum or non-platinum-based therapy. At present, there appear to be qualitative and quantitative differences in SAEs. Upon completion, we will definitively comment on the equivalence of a non-platinum-based treatment for this disease.